STOCK TITAN

Ironwood Pharmaceuticals to Participate in the Piper Sandler 35th Annual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Ironwood Pharmaceuticals, Inc. (IRWD) will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on November 29, 2023. The live webcast can be accessed through the Investors section of the company’s website. A replay will be available for 14 days following the conference.
Positive
  • None.
Negative
  • None.

BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023 at 9:00 a.m. ET at the Lotte New York Palace.

A live webcast of Ironwood’s fireside chat will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. To access the webcast, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Ironwood’s website for 14 days following the conference.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD), an S&P SmallCap 600® company, is a leading global gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. We are pioneers in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years-old. Ironwood is also advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF) as well as several earlier stage assets. Building upon our history of GI innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases and address significant unmet needs.

Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, and has additional operations in Basel, Switzerland.

We routinely post information that may be important to investors on our website at www.ironwoodpharma.com. In addition, follow us on X and on LinkedIn.

Investors:

Greg Martini, 617-374-5230

gmartini@ironwoodpharma.com



Matt Roache, 617-621-8395

mroache@ironwoodpharma.com



Media:

Beth Calitri, 978-417-2031

bcalitri@ironwoodpharma.com

Source: Ironwood Pharmaceuticals, Inc.

FAQ

When will Ironwood Pharmaceuticals participate in the Piper Sandler 35th Annual Healthcare Conference?

Ironwood Pharmaceuticals will participate in the conference on November 29, 2023.

Where can I access the live webcast of Ironwood Pharmaceuticals' fireside chat?

The live webcast can be accessed through the Investors section of Ironwood Pharmaceuticals' website.

How long will the replay of the webcast be available on Ironwood Pharmaceuticals' website?

The replay will be available for 14 days following the conference on Ironwood Pharmaceuticals' website.

Ironwood Pharmaceuticals, Inc. -

NASDAQ:IRWD

IRWD Rankings

IRWD Latest News

IRWD Stock Data

763.79M
158.96M
1.69%
110.22%
7.47%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
BOSTON